



(51) International Patent Classification:

A61K 9/00 (2006.01) A61K 31/56 (2006.01)
A61K 31/137 (2006.01) A61P 11/00 (2006.01)

(21) International Application Number:

PCT/US2016/014072

(22) International Filing Date:

20 January 2016 (20.01.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/105,479 20 January 2015 (20.01.2015) US

(71) Applicant: TEVA BRANDED PHARMACEUTICAL
PRODUCTS R&D, INC. [US/US]; 41 Moores Road,
Frazer, PA 19355 (US).

(72) Inventors: DALVI, Mukul; 845 Verona Lake Drive, We-
ston, FL 33326 (US). TEE, Seah, Kee; 1888 Aspen Lane,
Weston, FL 33327 (US).

(74) Agents: LEWIS, Christopher L. et al.; Ratnerprestia,
P.O. Box 980, Valley Forge, PA 19482 (US).


(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

[Continued on next page]

(54) Title: DRY POWDER INHALER COMPRISING FLUTICASONE PROPIONATE AND SALMETEROL XINAFOAT

(57) Abstract: This invention provides a dry powder inhaler comprising : a dry powder medicament comprising fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein, the delivered dose of fluticasone propionate per actuation is less than 100 µg; and wherein the dose provides a baseline-adjusted FEV₁ in a patient of more than 150 mL within 30 minutes of receiving the dose. A method of treating a patient includes administering to a patient a dry powder medicament having fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein, the delivered dose of fluticasone propionate per actuation is less than 100 µg; and wherein the dose provides a baseline-adjusted FEV₁ in a patient of more than 150 mL within 30 minutes of receiving the dose.





SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*